An observational study in Delirium and Cognitive Dysfunction, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 55 Years and older. Per ClinicalTrials.gov, last updated 2025-05-31.
Sponsored by Stanford University · Observational
The purpose of this study is to evaluate the effectiveness of the CGX/Lucidify EEG system in enabling physicians to detect delirium (confusion) in medically ill patients as early as possible in order to minimize the detrimental effects of delirium. The study will involve collecting EEG data through the CGX EEG system (a Research-grade 2-Channel EEG device) and applying the Lucidify EEG software algorithm to identify indicators and degree of delirium, obtain data regarding the amount and degree of patient's movement and activity throughout the day in order to detail delirium subtype, and obtain data regarding the quality of the sleep as it affects delirium severity and duration. By enhancing early detection, this research aims to improve patient outcomes and inform clinical decision-making.
Study investigators would like to use a portable electroencephalogram (pEEG), the CGX EEG system (a Research-grade 2-Channel EEG device) to measure the brainwaves of patients admitted to Stanford Medical Center. Study investigators will then use the Lucidify software to allow for the interpretation of obtained brainwaves in order to detect delirium as early as possible, in order to minimize the detrimental effects of delirium in cognition and behavior. The Lucidify algorithm, different from our previously utilized EEG system (see below for details) can provide two additional features not previously available: (1) accelerometer data (an indicator of the level of patient's movements and a proxy for delirium phenotype; and (2) scored polysomnography data (providing validated interpretation of the patient's spectral sleep - thus a true measure of the patient's various stages and quality of sleep; which has direct implications on both the progression of delirium and the patient's overall health and recovery). Finally, the CGX system is simpler, more comfortable to wear, and better tolerated by medically ill patients.
The primary objective is to monitor the development and progression of delirium (acute confusion) and sleep disturbances associated with medical illness over time. The study will focus on two distinct patient populations: 1) patients admitted to an adult intensive care unit (ICU), and 2) patients in oncology units with hematologic malignancies undergoing cellular therapies or hematopoietic stem cell transplants (e.g., stem cell and Chimeric Antigen Receptor T-cell (CAR-T) Therapy). The rationale for targeting the occurrence of delirium, as its development has been associated with significantly poor hospital care outcomes and increased morbidity (medical complications) and mortality (death). The two patient populations have been specifically selected for the following reasons: Delirium is frequently observed in the ICU setting, with a reported prevalence of up to 85%. In the hematologic malignancies undergoing cellular therapies or hematopoietic stem cell transplants population, there is a significant prevalence of neurotoxicity associated with delirium, ranging from 20% to 60%. This neurotoxicity can lead to comorbid risks such as seizures and cerebral edema, and it is also associated with long-term cognitive impairment and depression (Hayden 2022, Ruark 2020).
In comparison to other portable EEG devices, the CGX EEG system investigators intend to investigate during the course of this specific study is more user-friendly (i.e., smaller, more portable, and has no wirings attaching the patient to the bed or an external device) , allowing for continuous monitoring without patient discomfort or interference associated with other monitoring systems currently used in our ICU setting. In addition to this system's tolerability and simplicity, this new device and AI-algorithm allows for the acquisition of two significant variables not previously available: (a) its algorithm allows for accelerometer data acquisition (this is a measure of the patient's motion, which will constitute an ideal and objective measure of the delirium phenotype (e.g., hypoactive, hyperactive, or mixed delirium subtype); and (b) the system allows for the measurement of the various phases of the sleep cycle, thus providing a full hypnogram of the quality and duration of sleep. Taking advantage of the enhanced comfort of wearing this new system; given the waxing and waning nature of delirium (i.e., how quickly it can vary through the course of 24-hrs) and In order to take full advantage of the system's capabilities, study investigators need the CGX recorder to remain in place 24/7 for the duration of the study.
1,071 studies on the registry are indexed under Delirium; 239 are open to participants now.
This study's planned enrollment of 80 is below the median of 200 across 423 observational studies indexed under Delirium.
Browse Delirium studies →Stanford University is the lead sponsor of 2,161 studies on the registry; 428 are open to participants now.
Of its 268 completed or terminated interventional studies of FDA-regulated products, 207 (77%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects admitted to the ICU or Oncology hospital wards
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects admitted to the Intensive Care Unit (ICU)
Diagnostic Test: Electroencephalogram (EEG)
Subjects admitted to oncology units with hematologic malignancies undergoing cellular therapies or hematopoietic stem cell transplants (e.g., stem cell and Chimeric Antigen Receptor T-cell (CAR-T) Therapy)
Diagnostic Test: Electroencephalogram (EEG)
All study subjects will undergo monitoring via a portable electroencephalogram (pEEG), the CGX EEG system (a Research-grade 2-Channel EEG device) to measure the brainwaves of patients admitted to Stanford Medical Center. Investigators will then use the Lucidify software to allow for the interpretation of obtained brainwaves for the detection of delirium .
Number of subjects with delirium accurately diagnosed by the CGX EEG/Lucidify System
Record and collect EEG brain waves on study subjects using the CGX EEG/Lucidify System to assess EEG features to differentiate between delirium positive and delirium negative patients.
Time frame: 24-hours a day monitoring for a minimum of 3 days from enrollment to the end of the study period (maximum of 7 days post-enrollment)
Development of Delirium
Number of subjects diagnosed with delirium
Time frame: From enrollment to the end of the study period (maximum of 7 days post-enrollment)
Determination of Delirium Phenotype
For those who develop delirium, the phenotype of delirium will be determined as per the Liptzin-Levkoff Criteria (based on DSM diagnostic Criteria). As such, all delirium episodes will be categorized as: hyperactive, hypoactive, mixed, or subsyndromal delirium. In addition, this phenotype determination will be compared with the CGX/Lucidify EEG System accelerometer data to determine concordance between the two.
Time frame: From enrollment to the end of the study period (maximum of 7 days post-enrollment)
Immediate Post-hospital Admission Mortality
Mortality following admission to the ICU or oncology wards
Time frame: From date of admission up to time of discharge (assessed up to 1 year after admission)
Length of ICU & Hospital Stay
Total number of days admitted to the hospital
Time frame: From date of admission up to time of discharge of the ICU or oncology ward, and then from the hospital (assessed up to 1 year after admission)
Polysomnography Sleep Metrics - Stages of Sleep
Assessment of the quality of the various sleep stages.
Time frame: 24 hours a day for a maximum of 7 days
Polysomnography Sleep Metrics - Depth of sleep
Assessment of the quality of the depth of sleep.
Time frame: 24 hours a day for a maximum of 7 days
Polysomnography Sleep Metrics - Duration of Sleep
Assessment of the duration of sleep.
Time frame: 24 hours a day for a maximum of 7 days
Accelerometry Metrics - Acceleration Magnitude
Assessment of the overall acceleration experienced by the device, useful for assessing movement intensity to measure the amount and degree of patient motion as a proxy for delirium motoric phenotype.
Time frame: 24 hours a day for a maximum of 7 days
Accelerometry Metrics - Activity Counts
Assessment of the number of subject movement events detected.
Time frame: 24 hours a day for a maximum of 7 days
Accelerometry Metrics - Frequency of Movement
Assessment of the rate at which movements occur, which can indicate activity patterns specific to a delirium motoric phenotype.
Time frame: 24 hours a day for a maximum of 7 days
Accelerometry Metrics - Duration of Activity
Assessment of the total time spent in different activity states, which can be indicative of a specific delirium motoric phenotype.
Time frame: 24 hours a day for a maximum of 7 days
Accelerometry Metrics - Movement Variability
Assessment of the variability in movement patterns, which can be indicative of a delirium motoric phenotype.
Time frame: 24 hours a day for a maximum of 7 days
Plan to share: No
No publications or documents are linked to this record.
This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.